1. Field of the Invention
The invention relates generally to medical devices. More specifically, the invention relates to intravascular embolic protection devices.
2. Related Technology
Embolic protection devices are percutaneously placed in a body vessel to prevent emboli from traveling and creating an undesirable embolism, e.g., pulmonary embolism. For example, vena cava filters are being used for trapping emboli in the vena cava filter to prevent pulmonary embolism. Also, anti-platelet agents and anticoagulants may be used to breakdown blood clots. Moreover, snares and baskets (e.g., stone retrieval baskets) are being used for retrieving urinary calculi. Additionally, occlusion coils are commonly used to occlude aneurysms and accumulate thrombi in a body vessel.
Treatments for a stenotic lesion provide a potential in releasing blood clots and other thrombi plaque in the vasculature of the patient. One example is the treatment for a carotid artery stenosis. Generally, carotid artery stenosis is the narrowing of the carotid arteries, the main arteries in the neck that supply blood to the brain. Carotid artery stenosis (also called carotid artery disease) is a relatively high risk factor for ischemic stroke. The narrowing is usually caused by plaque build-up in the carotid artery.
Carotid angioplasty is a more recently developed treatment for carotid artery stenosis. This treatment uses balloons and/or stents to open a narrowed portion of an artery. Carotid angioplasty is a procedure that can be performed via a standard percutaneous transfemoral approach with the patient anesthetized using light intravenous sedation. At the stenosis area, an angioplasty balloon is delivered to predilate the stenosis in preparation for stent placement. The balloon is then removed and exchanged via catheter for a stent delivery device. Once in position, a stent is deployed across the stenotic area. If needed, an additional balloon can be placed inside the deployed stent for post-dilation to make sure the struts of the stent are pressed firmly against the inner surface of the vessel wall. During the stenosis procedure however, such as during the predilation or during the stent delivery, there is a risk of such blood clots and thrombi being undesirably released into the blood flow within the vasculature.
Therefore, embolic protection devices, such as occlusive devices and filters, have been developed to trap and to prevent the downstream travel of the blood clots and thrombi. The filters are typically advanced downstream of a site that is to be treated and then expanded into an opened state to increase the filter area. The blood clots and thrombi can be captured in the opened filter while blood is still able to flow therethrough.
Once the stenosis procedure has been completed, the stent delivery device is removed from the stenotic area and is possibly removed completely from the body vessel. Next, after the blood clots and thrombi displaced by the angioplasty have been captured in the opened filter, the embolic protection device is removed from the body vessel. However, to prevent the captured blood clots and thrombi from being released back into the blood stream, the embolic protection device preferably includes a mechanism for securing the blood clots and thrombi during removal of the embolic protection device. Furthermore, to facilitate the removal of the embolic protection device and to minimize or prevent additional blood clots and thrombi from being released from the stenotic area, the embolic protection device preferably has a relatively small cross-sectional area during the removal thereof.
However, currently known filter devices may fail to completely secure the blood clots and thrombi during removal of the embolic protection device. As another drawback, currently known filter devices may not sufficiently radially collapse the filter device before or during extraction from the body vessel. Additionally, or alternatively, currently known filter devices may require relatively bulky components to employ or control the mechanism for securing the blood clots and thrombi.
Thus, there is a need to improve the cross-sectional size of the embolic protection device during extraction from the body vessel and a need to improve the mechanism for securing the blood clots and thrombi during the extraction.
In one aspect of the present invention, an embolic protection device for deployment in a body vessel is provided for filtering emboli within the body vessel. The embolic protection device generally includes a filter having a plurality of openings formed therethrough and an extraction element configured to be movable with respect to the filter between a non-extraction position and an extraction position. The extraction element is located distally from the filter when in the non-extraction position so as to allow the filter to open into an expanded state to collect the emboli. Additionally, the extraction element is disposed about at least a portion of the filter when in the extraction position so as to close the filter into a collapsed state, to secure the collected emboli, and to permit the embolic protection device to be extracted from the body vessel.
In another aspect of the invention, the extraction element is an extraction sleeve. As an alternative design, the extraction element includes an extraction wire defining a loop. The extraction wire also may define a plurality of closed loops that are movable with respect to each other. In yet another alternative design, the extraction wire defines a coiled wire.
In yet another aspect, the filter includes a first filter element and a second filter element spaced apart from each other. Additionally, the first filter element defines a plurality of first filter openings and the second filter element defines a plurality of second filter openings, where the first filter openings are each larger than the second filter openings. The filter may also include a third filter element spaced apart from the first and the second filter elements.
In another aspect, the first filter openings decrease in size between a proximal portion and a distal portion of the first filter element and the second filter openings decrease in size between a proximal portion and a distal portion of the second filter element. This configuration promotes a complete self-expansion of each of the filter elements within the body vessel.
In yet another aspect of the present invention, the embolic protection device includes a delivery element that is movable with respect to the filter between a delivery position and a non-delivery position. The delivery element is disposed about at least a portion of the filter when in the delivery position so that the filter is in a collapsed state for delivery of the embolic protection device within the body vessel. Additionally, the delivery element is located proximally from the filter when in the non-delivery position so as to allow the filter to open into an expanded state and facilitate collection of the emboli.
The embolic protection device may also include: a filter control wire coupled with the filter to control the position thereof, an extraction control wire coupled with the extraction element to control the position thereof, and a delivery control wire coupled with the delivery element and to control the position thereof. In one design, the filter control wire is a hollow wire defining a conduit that receives at least a portion of the extraction control wire and at least a portion of the delivery control wire. Additionally, the outer diameter of the filter control wire is preferably substantially greater than each of the outer diameters of the extraction control wire and the delivery control wire.
In another aspect of the present invention, an assembly for removing emboli from a body vessel is provided. The assembly generally includes an inflatable catheter having an expanded state for expanding narrowed or restricted portions of the body vessel, an outer catheter for delivering the inflatable catheter into the body vessel, and an embolic protection device positioned distally of the inflatable catheter for collecting emboli that are potentially dislodged during expansion of the body vessel.
In another aspect of the present invention, an embolic protection device includes a first filter element and a second filter element, each having a proximal end and a distal end. The proximal end of the second filter element is connected to an outer surface of the first filter element to stabilize the filter elements and to prevent emboli from flowing around the embolic protection device.
The first filter element and the second filter element preferably overlap each other to define an overlapping distance along the longitudinal axis of the embolic protection device. Additionally, or alternatively, the embolic protection device includes a third filter element having a proximal end and a distal end, wherein the proximal end of the third filter element is connected to an outer surface of the second filter element. The three filter elements cooperate to define a substantially constant outer diameter between the proximal end of the first filter element and the distal end of the third filter element.
The second plurality of openings are generally smaller than the first plurality of openings and the third plurality of openings are generally smaller than the second plurality of openings so that the first filter element collects relatively large emboli, the second filter element collects medium-sized emboli, and the third filter element collects relatively small emboli.
Further objects, features and advantages of this invention will become readily apparent to persons skilled in the art after a review of the following description, with reference to the drawings and claims that are appended to and form a part of this specification.
Embodiments of the present invention generally provide embolic protection devices, embolic protection apparatus, and methods for capturing emboli in a body vessel during angioplasty for treatment of a stenosis. One particular stenosis is a carotid artery stenosis. The embodiments reduce the concerns of current stenosis treatments, such as the relatively high risks of surgery and the potential release of emboli into the vasculature during the stenosis procedure. For example, embodiments of the present invention provide a relatively low risk approach to capturing emboli released during a stenosis procedure, e.g., balloon angioplasty.
Referring now to the drawings,
The filter elements 26a, 26b, 26c each preferably include an open, proximally-located lip portion 30a, 30b, 30c that selectively expands to receive the emboli 24 and a closed, distally-located base portion 36a, 36b, 36c to collect and/or store the emboli 24. The lip portion 30a, 30b, 30c is movable so that the embolic protection device 20 defines a collapsed state 32 (
The filter 26, when in the expanded state 34, preferably has a generally decreasing radius such that a first cross-sectional area of the filter 26 taken along a plane adjacent to the lip portion 30 is substantially larger than a second cross-sectional area of the filter 26 taken along a second plane adjacent to the base portion 36. For example, the expanded state 34 filter 26 is preferably generally cone-shaped such as to have a constantly decreasing radius along a longitudinal axis. In the design shown in the figures, each of the individual filter elements 26a, 26b, 26c is generally cone-shaped.
The filter 26 may be made of any suitable filter material to be used for capturing emboli 24 from the stenotic lesion during treatment thereof. In one embodiment, the filter 26 is coated with or made of reconstituted or naturally-derived collagenous materials. Such materials that are at least bioresorbable will provide advantage in the present invention, with materials that are bioremodelable and promote cellular invasion and ingrowth providing particular advantage.
Suitable bioremodelable materials can be provided by collagenous extracellular matrix materials (ECMs) possessing biotropic properties, including in certain forms angiogenic collagenous extracellular matrix materials. For example, suitable collagenous materials include ECMs such as submucosa, renal capsule membrane, dermal collagen, dura mater, pericardium, fascia lata, serosa, peritoneum or basement membrane layers, including liver basement membrane. Suitable submucosa materials for these purposes include, for instance, intestinal submucosa, including small intestinal submucosa, stomach submucosa, urinary bladder submucosa, and uterine submucosa.
As prepared, the submucosa material and any other ECM used may optionally retain growth factors or other bioactive components native to the source tissue. For example, the submucosa or other ECM may include one or more growth factors such as basic fibroblast growth factor (FGF-2), transforming growth factor beta (TGF-beta), epidermal growth factor (EGF), and/or platelet derived growth factor (PDGF). As well, submucosa or other ECM used in the invention may include other biological materials such as heparin, heparin sulfate, hyaluronic acid, fibronectin and the like. Thus, generally speaking, the submucosa or other ECM material may include a bioactive component that induces, directly or indirectly, a cellular response such as a change in cell morphology, proliferation, growth, protein or gene expression.
Submucosa or other ECM materials of the present invention can be derived from any suitable organ or other tissue source, usually sources containing connective tissues. The ECM materials processed for use in the invention will typically include abundant collagen, most commonly being constituted at least about 80% by weight collagen on a dry weight basis. Such naturally-derived ECM materials will for the most part include collagen fibers that are non-randomly oriented, for instance occurring as generally uniaxial or multi-axial but regularly oriented fibers. When processed to retain native bioactive factors, the ECM material can retain these factors interspersed as solids between, upon and/or within the collagen fibers. Particularly desirable naturally-derived ECM materials for use in the invention will include significant amounts of such interspersed, non-collagenous solids that are readily ascertainable under light microscopic examination with specific staining. Such non-collagenous solids can constitute a significant percentage of the dry weight of the ECM material in certain inventive embodiments, for example at least about 1%, at least about 3%, and at least about 5% by weight in various embodiments of the invention.
The submucosa or other ECM material used in the present invention may also exhibit an angiogenic character and thus be effective to induce angiogenesis in a host engrafted with the material. In this regard, angiogenesis is the process through which the body makes new blood vessels to generate increased blood supply to tissues. Thus, angiogenic materials, when contacted with host tissues, promote or encourage the infiltration of new blood vessels. Methods for measuring in vivo angiogenesis in response to biomaterial implantation have recently been developed. For example, one such method uses a subcutaneous implant model to determine the angiogenic character of a material. See, C. Heeschen et al., Nature Medicine 7 (2001), No. 7, 833-839. When combined with a fluorescence microangiography technique, this model can provide both quantitative and qualitative measures of angiogenesis into biomaterials. C. Johnson et al., Circulation Research 94 (2004), No. 2, 262-268.
Further, in addition or as an alternative to the inclusion of native bioactive components, non-native bioactive components such as those synthetically produced by recombinant technology or other methods, may be incorporated into the submucosa or other ECM tissue. These non-native bioactive components may be naturally-derived or recombinantly produced proteins that correspond to those natively occurring in the ECM tissue, but perhaps of a different species (e.g. human proteins applied to collagenous ECMs from other animals, such as pigs). The non-native bioactive components may also be drug substances. Illustrative drug substances that may be incorporated into and/or onto the ECM materials used in the invention include, for example, antibiotics or thrombus-promoting substances such as blood clotting factors, e.g. thrombin, fibrinogen, and the like. These substances may be applied to the ECM material as a premanufactured step, immediately prior to the procedure (e.g. by soaking the material in a solution containing a suitable antibiotic—such as cefazolin), or during or after engraftment of the material in the patient.
Submucosa or other ECM tissue used in the invention is preferably highly purified, for example, as described in U.S. Pat. No. 6,206,931 to Cook et al. Thus, preferred ECM material will exhibit an endotoxin level of less than about 12 endotoxin units (EU) per gram, more preferably less than about 5 EU per gram, and most preferably less than about 1 EU per gram. As additional preferences, the submucosa or other ECM material may have a bioburden of less than about 1 colony forming units (CFU) per gram, more preferably less than about 0.5 CFU per gram. Fungus levels are desirably similarly low, for example less than about 1 CFU per gram, more preferably less than about 0.5 CFU per gram. Nucleic acid levels are preferably less than about 5 μg/mg, more preferably less than about 2 μg/mg, and virus levels are preferably less than about 50 plaque forming units (PFU) per gram, more preferably less than about 5 PFU per gram. These and additional properties of submucosa or other ECM tissue taught in U.S. Pat. No. 6,206,931 may be characteristic of the submucosa tissue used in the present invention.
In this embodiment, the submucosa or other ECM material is used to temporarily adhere the filter 26 to the walls of a body vessel in which the embolic protection device 20 is deployed. As discussed above, the submucosa or other ECM material has a natural adherence or wettability to body fluids and connective cells comprising the connective tissue of a body vessel wall. Due to the temporary nature of the duration in which the embolic protection device 20 is deployed in the body vessel, host cells of the wall will adhere to the filter 26 but not differentiate, allowing for retrieval of the embolic protection device 20 from the blood vessel 22.
In other embodiments, the filter 26 may also or alternatively be made of a mesh/net cloth, nylon, polymeric material, Teflon, or woven mixtures thereof without falling beyond the scope or spirit of the present invention.
Each of the filter elements 26a, 26b, 26c also preferably includes a plurality of struts 38 (
The struts 38 may be comprised of any suitable material such as a superelastic material, stainless steel wire, cobalt-chromium-nickel-molybdenum-iron alloy, or cobalt-chrome alloy. It is understood that the struts 38 may be formed of any other suitable material, such as shape memory alloys. Shape memory alloys have the desirable property of returning to a remembered state when heated above a transition temperature. A shape memory alloy suitable for the present invention is a mixture of Nickel and Titanium available under the more commonly known name Nitinol. When this material is heated above the transition temperature, the material undergoes a phase transformation from martensite to austenic, such that material returns to its remembered state. The transition temperature is dependent on the relative proportions of the alloying elements Nickel and Titanium and the optional inclusion of alloying additives.
In one embodiment, the struts 38 are made from Nitinol with a transition temperature that is slightly below normal body temperature of humans, which is about 98.6 degrees Fahrenheit. Therefore, when the filter 26 is deployed in the blood vessel 22 and exposed to normal body temperature, the alloy of the struts 38 will transform to austenite, that is, the remembered state, which for one embodiment of the present invention is the expanded configuration when the filter 26 is deployed in the blood vessel 22, as will be discussed in more detail below.
Each of the filter elements 26a, 26b, 26c also preferably includes a frame 40 positioned at or adjacent to the lip portion 30a, 30b, 30c to form a substantially fluid-tight seal with the blood vessel 22. More specifically, when the filter 26 is in the expanded state 34, the frame 40 defines a generally circular shape so as to generally conform to the shape the blood vessel 22. The seal substantially prevents emboli 24 from flowing around the filter 26 and causing the above-described conditions.
However, the frame 40 is also preferably able to be radially collapsed when the filter 26 is in the collapsed state 32. For example, the frame 40 may include a plurality of flexible, telescoping portions so that the frame 40 remains a generally circular component with an adjustable radius, whether the frame 40 is in the collapsed state 32 or the expanded state 34. This design may be particularly advantageous because it allows the embolic protection device 20 to be used in blood vessels 22 of varying size while still retaining a generally circular shape. Alternatively, the frame 40 may include a plurality of generally rigid portions that are hingedly connected with each other so that the frame 40 is generally circular when in the expanded state 34 and is non-circular, such as a star shape, when the frame 26 is in the collapsed state 32. As yet another alternative design, the frame 40 may be a single component with a plurality of weakened portions to permit the frame 40 to collapse into a non-circular shape, such as a star shape, when the frame 26 is in the collapsed state 32.
In another alternative design, the filter 26 does not include a frame, and the struts 38 provide sole structural support for the filter material. This design may be particularly advantageous because it allows the embolic protection device 20 to be used in blood vessels 22 having varying sizes. In yet another alternative design, the filter 26 does not include a frame or struts, and the filter material is not structurally supported by any additional components. In this design, and preferably in the other designs described herein, the filter material is naturally expanded into the expanded state 34 by forces from the blood stream 25 flowing through the blood vessel 22.
The openings 28 defined by the filter elements 26a, 26b, 26c are preferably configured such as to effectively harness the blood stream 25 and to promote the natural expansion of filter 26. For example, referring to
Regarding the base portion 36, the distal openings 44 are relatively small so as to cause a flow resistance that is sufficient to open the filter 26. More specifically, the distal openings 44 are sized and positioned with respect to each other such that the filter 26 provides a flow resistance when the base portion 36 is folded. Therefore, when the filter 26 is in the collapsed state 32, such as when being initially deployed into the blood vessel 22, the filter 26 may become folded along creases such that some of the openings 28 become blocked. Therefore, the distal openings 44 are sized and positioned with respect to each other such as to provide a flow resistance unless substantially all of the distal openings 44 are unobstructed, thereby causing the filter 26 to naturally expand.
However, the distal openings 44 are preferably not so small as to restrict blood flow there through when the base portion 36 is fully opened and unobstructed. As discussed above, restricted blood flow can cause various undesirable medical conditions. Therefore, the distal openings 44 are large enough such as to not reduce blood flow through the filter 26.
The distal openings 44 are preferably located along an end face 46 of the filter 26 that is substantially perpendicular to the direction of the blood stream 25. This configuration also causes the filter 26 to fully open because the openings along the end face 46 have a maximum effective area when positioned to be perpendicular to the blood stream 25. Therefore, the natural properties of fluid flow will cause the end face 46 to be perpendicular to the direction of the blood stream 25, thus opening the filter 26 to its full length and maximizing its trapping volume.
Regarding the lip portion 30, the proximal openings 42 are relatively large to act as overflow passages for the distal openings 44 if they become obstructed. As emboli 24 flow into the filter 26 and engage the base portion 36, the distal openings 44 may become obstructed, thereby limiting the fluid flow through the base portion 36. To compensate for this reduced flow are, the proximal openings 42 have relatively large cross-sections. Therefore, the large proximal openings 42 substantially prevent the embolic protection device 20 from causing flow loss.
As shown in
The proximal openings 42 may serve as continuously-used passages, such that blood continuously flows through the proximal openings 42, whether the distal openings 44 are obstructed or unobstructed. However, due to the generally cone-shaped nature of the filter elements 26a, 26b, 26c, the radially central portion of the filter receives the majority of the flow therethrough. More specifically, the natural fluid properties of the blood flow, such as friction between the blood flow and the blood vessel walls, cause the radially central portion of the blood vessel 22 to have a higher mass flow volume than the radially outer portion of the blood vessel 22. Furthermore, the tapered shape of the filter elements 26a, 26b, 26c directs blood towards the base portion 36 and thus towards the distal openings 44.
In addition to maximizing the trapping volume of and minimizing the flow losses through, the filter 26 also includes features that maximize the radial expansion of the embolic protection device 20. More specifically, to effectively form a seal between the filter 26 and the blood vessel 22 and thus prevent emboli 24 from flowing past the filter 26, the embolic protection device 20 is configured such that blood flow causes the filter 26 to be radially opened until it engages the blood vessel 22 inner walls.
One such feature that radially opens the filter 26 is the generally cone-shaped design of the filter 26. This shape causes blood flow along the direction of the blood stream 25 to create an axial force component 50 and a radial force component 52. More specifically, the axial force component 50 extends the filter 28 along its length, as discussed above. Furthermore, the radial force component 52 extends the filter 26 outwardly in the radial direction, towards the blood vessel 22 inner walls. Therefore, the cone-shaped nature of the filter 26 improves the seal and increases the trapping volume of the device 20.
In the embodiment shown in the figures, another such feature that radially opens the filter 26, or maintains the opened state thereof is the submucosa or other ECM material promoting biofixation between the filter 26 and the body vessel 12 discussed above. More specifically, the outer surface of the filter 26 includes a connective tissue that causes biofixation between the outer surface of the filter 26 and the inner surface of the blood vessel 22, thereby sealing the respective components 26, 22 together. The connective tissue is located on the frame 26 and on a portion of the filter 26 immediately adjacent to the lip portion 30. Additionally, the connective tissue may be located on the outer surface along a length of the filter 26 such as to increase the surface area of the seal. As another design, the connective tissue may be a coating along the entire length of the filter 26. As yet another design, the filter material may be completely formed of the connective tissue.
Referring back to
In one configuration, each of the openings 28a in the first filter element 26a is larger than each of the openings 28b in the second filter element 26b and each of the openings 28b in the second filter element 26b is larger than each of the openings 28c in the third filter element 26c. In another configuration, the proximal openings in the in the first filter element 26a are larger than the proximal openings in the second filter element 26b and the distal openings in the in the first filter element 26a are larger than the distal openings in the second filter element 26b, but the proximal openings in the first filter element 26a are not larger than the distal openings in the second filter element 26b. In other words, in this configuration, the average size of the openings decreases from the first filter element 26a to the third filter element 26c, but some of the openings in the second or third filter elements 26b, 26c may still be smaller than some of the openings in the first filter element 26a. Alternatively, any suitable configuration of the openings may be used.
The above-described configuration is beneficial for reducing the cross-sectional area of the filter 26 when the emboli 24 are trapped therewithin. In other words, each of the filter elements 26a, 26b, 26c is able to collect a generally equal amount of emboli 24, thereby equally distributing the emboli 24 among the filter elements 26a, 26b, 26c. This configuration is particularly beneficial for reducing the cross-sectional area of the filter 26 when in the collapsed state 32, as will be discussed in more detail below.
Although three filter elements 26a, 26b, 26c are shown in the figures, any suitable number of elements may be used with the present invention. For example, a single filter element may be employed in the embolic protection device 20.
Generally, during use, the device 20 is inserted into the blood vessel 22 while in the collapsed state 32. Additionally, the device 20 is then expanded from the collapsed state 32 to the expanded state 34 so that the filter 26 engages the blood vessel 22. As a result, the lip portion 30 of each of the respective filter elements 26a, 26b, 26c opens for capturing emboli during treatment of the stenotic lesion. After the need for such device 20 in the vasculature passes, the device 20 may be closed to the collapsed state 32 and retrieved.
To illustrate a more specific example,
A method of utilizing the assembly 54 will now be discussed in more detail. First, as shown in
Next, as shown in
The seal preferably prevents emboli 24 from flowing between the filter 26 and the blood vessel inner wall 76, thereby preventing or minimizing the above-described conditions. The delivery sleeve 70 is preferably moved with respect to the filter 26 via a delivery control wire 78 that is able to be retracted with respect to the filter control wire 68, as will be discussed in more detail below. Although the delivery sleeve 70 is shown as being positioned between the stenotic lesion 66 and the filter 26 when in the non-delivery position 74, any suitable non-delivery position may be used. For example, the delivery sleeve 70 may be retracted over the assembly 54 and completely removed from the blood vessel 22.
Next, the expandable balloon 64 is expanded into a partially-expanded state 80 (
Next, as shown in
As shown in
As is known in the art, the term “proximal” refers to the portion of the embolic protection device 20 that is not positioned within the body vessel 22 during normal use of the embolic protection device 20 and the term “distal” refers to the opposing portion of the embolic protection device 20, which may be positioned within the body vessel 22. Therefore, when the extraction sleeve 84 is moved from the non-extraction position 86 to the extraction position 88, the device 20 is moved proximally. Similarly, when the embolic protection device 20 is extracted from the body vessel 22, it is likewise moved proximally. In this configuration, the filter 26 is collapsed into the extraction position 88 in the same direction as the direction of travel during extraction, thereby potentially reducing the likelihood that emboli escape from the filter 26 while the filter 26 is being collapsed.
The extraction sleeve 84 is preferably moved with respect to the filter 26 via an extraction control wire 90 that is able to be retracted with respect to the filter control wire 68, as will be discussed in more detail below.
When the filter 26 is in the collapsed state 32, the diameter is substantially reduced, thereby effectively securing the emboli 24 in the respective filters 26a, 26b, 26c and reducing the overall diameter of the embolic protection device 20 so that it can be retracted through the outer catheter 60. The assembly 54 discussed herein may be used with any other suitable procedure.
In the embodiment shown in
Referring to
The coiled wire 92 defines a hollow conduit 94 extending along the filter control wire 68 and providing guidance for portions of the embolic protection device 20. For example, the delivery control wire 78 and the extraction control wire 90 extend at least partially along the conduit 94 for guidance through the blood vessel 22 and for space efficiency. More specifically, as shown in
Because the delivery sleeve 70 and the extraction sleeve 84 are only moving in a proximal direction with respect to the filter 26 during the above-described treatment, the respective sleeves 70, 84 may be controlled by pulling on the respective control wires 78, 90 and/or pushing on the filter control wire 68. Therefore, because the respective control wires 78, 90 are only pulled and not pushed, they do not require a relatively high axial stiffness compared to the filter control wire 68 and thereby do not require a relatively high cross-sectional area compared to the filter control wire 68. This configuration is especially beneficial because the delivery control wire 78 and the extraction control wire 90 are more easily positioned within the conduit 94 to reduce the space of the embolic protection device 20.
In one example, referring to
Referring now to
When in the extraction position 288, the extraction wire 285 is disposed about the filter 226 so that the filter elements 226a, 226b, 226c are compressed into a collapsed state 232 having a relatively small collapsed diameter 289 for extraction from the blood vessel 222. The extraction wire 285 is moved from the non-extraction position 286 to the extraction position 288 by an extraction control wire 290. For example, a physician is able to pull on the extraction control wire 290 while holding the filter control wire 68 steady. The embolic protection device 220 shown in
Referring now to
When in the extraction position 388, the extraction wire 385 is disposed about the filter 326 so that the filter elements 326a, 326b, 326c are compressed into a collapsed state 332 having a relatively small collapsed diameter 289 for extraction from the blood vessel 322. More specifically, the extraction wire 385 includes a single loop 387a that surrounds the first filter element 326a so that the first filter element 326a is compressed into a collapsed state 332 for extraction from the blood vessel 322. Similarly, two other extraction wires 385b, 385c define single loops 387b, 387c that surround the second and third filter elements 326b, 326c respectively so that the filter elements 326b, 326c are also compressed into the collapsed state 332. The three extraction wires 385a, 385b, 385c may be controlled by a single control wire so that they can be simultaneously deployed into the extraction position 388, or they can be independently controlled. This configuration is especially advantageous because the three loops 387a, 387b, 387c can be stored in an axially compressed state when in the non-extraction position 386 to reduce the axial length of the embolic protection device 320. The extraction wire 385 is moved from the non-extraction position 386 to the extraction position 388 by an extraction control wire 390. For example, a physician is able to pull on the extraction control wire 390 while holding the filter control wire 368 steady.
The extraction element 384 may alternatively be positioned such that, when in the non-extraction position 386, each of the three loops 387a, 387b, 387c is positioned immediately distally one of the filters 326a, 326b, 326c. More specifically, when in the non-extraction position 386, the first loop 387a is positioned between the first and second filters 326a, 326b; the second loop 387b is positioned between the second and third filters 326b, 326c; and the third loop 387c is positioned immediately distally of the third filter 326c.
Referring now to
Furthermore, the respective filter elements 426a, 426b, 426c are preferably connected to each other to stabilize the embolic protection device 420 and to prevent emboli from flowing around the embolic protection device. More specifically, a proximal end 508 of the second filter element 426b is connected to an outer surface 510 of the first filter element 426a and a proximal end 512 of the third filter element 426c is connected to an outer surface 514 of the second filter element 426b. The emboli 24 that flow into the mouth portion of the embolic protection device 420 therefore remain within one of the filters element 426a, 426b, 426c even after flowing through an opening in the proximally-located filter element. In other words, the embolic protection device 420 shown in
In this design, the respective filter elements 426a, 426b, 426c cooperate to define a generally constant outer diameter 516 between a proximal end 518 of the first filter element 426a and a distal end 520 of the third filter element 426c. The substantially constant outer diameter 516 of the filter elements 426a, 426b, 426c improves the sealing connection between the embolic protection device 420 and the blood vessel 22, thereby reducing the number of emboli 24 that flow past the embolic protection device 420. Furthermore, the connections between the respective filter elements 426a, 426b, 426c prevent the individual filter elements from undesirably turning within the blood vessel 22 and otherwise stable the embolic protection device 420.
The first filter element 426a defines a first plurality of openings 522 so that the first filter element 426a is designed to capture relatively large emboli 24a. Additionally, the second filter element 426b defines a second plurality of openings 524 that are smaller than the first plurality of openings 522 so that the second filter element 426b is designed to capture medium-sized emboli 24b. Similarly, the third filter element 426c defines a third plurality of openings 526 that are smaller than the second plurality of openings 524 so that the third filter element 426c is designed to capture relatively small emboli 24c. As with the design shown in
The center core wire 500 of the embolic protection device 420 guides the respective filter elements 426a, 426b, 426c within the blood vessel 22 and properly positions the elements 426a, 426b, 426c with respect to each other. For example, each of the filter elements 426a, 426b, 426c includes a sliding sleeve 528, 530, 532 attached to the distal end thereof 534, 536, 520 that receives and that is freely slidable along the center core wire 500. Therefore, the sliding sleeves 528, 530, 532 are able to slide along the center core wire 500 during deployment into the blood vessel 22 and during extraction therefrom, as will be discussed in further detail below. Furthermore, the sliding sleeves 528, 530, 532 radially position the filter elements 426a, 426b, 426c within the blood vessel 22 during emboli collection.
The embolic protection device 420 is moved between an expanded state 434 (shown in
In an alternative design, the filter elements 426a, 426b, 426c include frame portions made of a relatively elastic material, such as a super elastic metal, to ease the opening and closing of the embolic protection device 420. In yet another design, a delivery sleeve and/or an extraction sleeve are included to deliver and extract the emboli protection device 420, as described above.
It is therefore intended that the foregoing detailed description be regarded as illustrative rather than limiting, and that it be understood that it is the following claims, including all equivalents, that are intended to define the spirit and scope of this invention.
This patent application claims the benefit under 35 U.S.C. §119(e) of U.S. provisional patent application Ser. No. 60/723,255, filed Oct. 3, 2005 and entitled EMBOLIC PROTECTION DEVICE, the entire contents of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3108593 | Glassman | Oct 1963 | A |
3334629 | Cohn | Aug 1967 | A |
3472230 | Fogarty | Oct 1969 | A |
3547103 | Cook | Dec 1970 | A |
3635223 | Klieman | Jan 1972 | A |
3923065 | Nozick et al. | Dec 1975 | A |
3952747 | Kimmell, Jr. | Apr 1976 | A |
3978863 | Fettel et al. | Sep 1976 | A |
3996938 | Clark, III | Dec 1976 | A |
4425908 | Simon | Jan 1984 | A |
4456000 | Schjeldahl et al. | Jun 1984 | A |
4494531 | Gianturco | Jan 1985 | A |
4548206 | Osborne | Oct 1985 | A |
4561439 | Bishop et al. | Dec 1985 | A |
4562039 | Koehler | Dec 1985 | A |
4604094 | Shook | Aug 1986 | A |
4619246 | Molgaard-Nielsen et al. | Oct 1986 | A |
4643184 | Mobin-Uddin | Feb 1987 | A |
4646736 | Auth | Mar 1987 | A |
4650472 | Bates | Mar 1987 | A |
4665906 | Jervis | May 1987 | A |
4669464 | Sulepov | Jun 1987 | A |
4688553 | Metals | Aug 1987 | A |
4723549 | Wholey et al. | Feb 1988 | A |
4727873 | Mobin-Uddin | Mar 1988 | A |
4732152 | Wallsten et al. | Mar 1988 | A |
4817600 | Herms et al. | Apr 1989 | A |
4824435 | Giesy et al. | Apr 1989 | A |
4832055 | Palestrant | May 1989 | A |
4846794 | Hertzer | Jul 1989 | A |
4848343 | Wallsten et al. | Jul 1989 | A |
4873978 | Ginsburg | Oct 1989 | A |
4943297 | Saveliev et al. | Jul 1990 | A |
4957501 | Lahille et al. | Sep 1990 | A |
4990156 | Lefebvre | Feb 1991 | A |
4998916 | Hammerslag et al. | Mar 1991 | A |
5053008 | Bajaj | Oct 1991 | A |
5059205 | El-Nounou et al. | Oct 1991 | A |
5069226 | Yamauchi et al. | Dec 1991 | A |
5078726 | Kreamer | Jan 1992 | A |
5100423 | Fearnot | Mar 1992 | A |
5108418 | Lefebvre | Apr 1992 | A |
5108419 | Reger et al. | Apr 1992 | A |
5112347 | Taheri | May 1992 | A |
5129890 | Bates et al. | Jul 1992 | A |
5133733 | Rasmussen et al. | Jul 1992 | A |
5147379 | Sabbaghian et al. | Sep 1992 | A |
5152777 | Goldberg | Oct 1992 | A |
5160342 | Reger | Nov 1992 | A |
5163927 | Woker et al. | Nov 1992 | A |
5203772 | Hammerslag et al. | Apr 1993 | A |
5234458 | Metais | Aug 1993 | A |
5242462 | El-Nounou | Sep 1993 | A |
5243996 | Hall | Sep 1993 | A |
5251640 | Osborne | Oct 1993 | A |
5263964 | Purdy | Nov 1993 | A |
5300086 | Gory et al. | Apr 1994 | A |
5324304 | Rasmussen | Jun 1994 | A |
5329942 | Gunther et al. | Jul 1994 | A |
5344427 | Cottenceau et al. | Sep 1994 | A |
5350397 | Palermo et al. | Sep 1994 | A |
5350398 | Pavcnik et al. | Sep 1994 | A |
5364345 | Lowery et al. | Nov 1994 | A |
5370657 | Irie | Dec 1994 | A |
5375612 | Cottenceau et al. | Dec 1994 | A |
5383887 | Nadal | Jan 1995 | A |
5413586 | Dibie et al. | May 1995 | A |
5415630 | Gory et al. | May 1995 | A |
5417708 | Hall et al. | May 1995 | A |
5451233 | Yock | Sep 1995 | A |
5458573 | Summers | Oct 1995 | A |
5522881 | Lentz | Jun 1996 | A |
5527338 | Purdy | Jun 1996 | A |
5531788 | Dibie et al. | Jul 1996 | A |
5549551 | Peacock et al. | Aug 1996 | A |
5549626 | Miller et al. | Aug 1996 | A |
5556414 | Turi | Sep 1996 | A |
5562698 | Parker | Oct 1996 | A |
5571135 | Fraser et al. | Nov 1996 | A |
5591195 | Taheri et al. | Jan 1997 | A |
5601595 | Smith | Feb 1997 | A |
5624461 | Mariant | Apr 1997 | A |
5626605 | Irie et al. | May 1997 | A |
5630797 | Diedrich et al. | May 1997 | A |
5634942 | Chevillon et al. | Jun 1997 | A |
5649953 | Lefebvre | Jul 1997 | A |
5662703 | Yurek et al. | Sep 1997 | A |
5669933 | Simon et al. | Sep 1997 | A |
5681347 | Cathcart et al. | Oct 1997 | A |
5690642 | Osborne et al. | Nov 1997 | A |
5690667 | Gia | Nov 1997 | A |
5693067 | Purdy | Dec 1997 | A |
5693087 | Parodi | Dec 1997 | A |
5695518 | Laerum | Dec 1997 | A |
5695519 | Summers et al. | Dec 1997 | A |
5700253 | Parker | Dec 1997 | A |
5709704 | Nott et al. | Jan 1998 | A |
5713853 | Clark et al. | Feb 1998 | A |
5720764 | Naderlinger | Feb 1998 | A |
5725550 | Nadal | Mar 1998 | A |
5738667 | Solar | Apr 1998 | A |
5746767 | Smith | May 1998 | A |
5755772 | Evans et al. | May 1998 | A |
5755790 | Chevillon et al. | May 1998 | A |
5766203 | Imran et al. | Jun 1998 | A |
5769816 | Barbut et al. | Jun 1998 | A |
5769871 | Mers et al. | Jun 1998 | A |
5795322 | Boudewijn | Aug 1998 | A |
5800457 | Gelbfish et al. | Sep 1998 | A |
5800525 | Bachinski et al. | Sep 1998 | A |
5810874 | Lefebvre | Sep 1998 | A |
5814027 | Hassett et al. | Sep 1998 | A |
5814064 | Daniel et al. | Sep 1998 | A |
5820592 | Hammerslag | Oct 1998 | A |
5827324 | Cassell et al. | Oct 1998 | A |
5830230 | Berryman et al. | Nov 1998 | A |
5836968 | Simon et al. | Nov 1998 | A |
5836969 | Kim et al. | Nov 1998 | A |
5846260 | Maahs | Dec 1998 | A |
5853420 | Chevillon et al. | Dec 1998 | A |
5876367 | Kaganov et al. | Mar 1999 | A |
5893869 | Barnhart et al. | Apr 1999 | A |
5895391 | Farnholtz | Apr 1999 | A |
5895399 | Barbut et al. | Apr 1999 | A |
5895410 | Forber et al. | Apr 1999 | A |
5908435 | Samuels | Jun 1999 | A |
5910154 | Tsugita et al. | Jun 1999 | A |
5911702 | Romley et al. | Jun 1999 | A |
5911704 | Humes | Jun 1999 | A |
5911717 | Jacobsen et al. | Jun 1999 | A |
5911734 | Tsugita et al. | Jun 1999 | A |
5919224 | Thompson et al. | Jul 1999 | A |
5925062 | Purdy | Jul 1999 | A |
5925063 | Khosravi | Jul 1999 | A |
5928260 | Chine et al. | Jul 1999 | A |
5928261 | Ruiz | Jul 1999 | A |
5938683 | Lefebvre | Aug 1999 | A |
5941896 | Kerr | Aug 1999 | A |
5944728 | Bates | Aug 1999 | A |
5947985 | Imran | Sep 1999 | A |
5947995 | Samuels | Sep 1999 | A |
5948017 | Taheri | Sep 1999 | A |
5951567 | Javier, Jr. et al. | Sep 1999 | A |
5954741 | Fox | Sep 1999 | A |
5954742 | Osypka | Sep 1999 | A |
5954745 | Gertler et al. | Sep 1999 | A |
5968057 | Taheri | Oct 1999 | A |
5968071 | Chevillon et al. | Oct 1999 | A |
5972019 | Engelson et al. | Oct 1999 | A |
5976162 | Doan et al. | Nov 1999 | A |
5976172 | Homsma et al. | Nov 1999 | A |
5980555 | Barbut et al. | Nov 1999 | A |
5984947 | Smith | Nov 1999 | A |
5984965 | Knapp et al. | Nov 1999 | A |
5989281 | Barbut et al. | Nov 1999 | A |
6001118 | Daniel et al. | Dec 1999 | A |
6007557 | Ambrisco et al. | Dec 1999 | A |
6007558 | Ravenscloth et al. | Dec 1999 | A |
6010522 | Barbut et al. | Jan 2000 | A |
6013093 | Nott et al. | Jan 2000 | A |
6015424 | Rosenbluth et al. | Jan 2000 | A |
6027520 | Tsugita et al. | Feb 2000 | A |
6036717 | Mers Kelly et al. | Mar 2000 | A |
6036720 | Abrams et al. | Mar 2000 | A |
6042598 | Tsugita et al. | Mar 2000 | A |
6051014 | Jang | Apr 2000 | A |
6051015 | Maahs | Apr 2000 | A |
6053932 | Daniel et al. | Apr 2000 | A |
6059745 | Gelbfish | May 2000 | A |
6059814 | Ladd | May 2000 | A |
6063113 | Kavteladze et al. | May 2000 | A |
6066158 | Engelson et al. | May 2000 | A |
6068645 | Tu | May 2000 | A |
6074357 | Kaganov et al. | Jun 2000 | A |
6077274 | Ouchi et al. | Jun 2000 | A |
6080178 | Meglin | Jun 2000 | A |
6083239 | Addis | Jul 2000 | A |
6086577 | Ken et al. | Jul 2000 | A |
6086605 | Barbut et al. | Jul 2000 | A |
6093199 | Brown et al. | Jul 2000 | A |
6096053 | Bates | Aug 2000 | A |
6096070 | Ragheb et al. | Aug 2000 | A |
6099549 | Bosma et al. | Aug 2000 | A |
6106497 | Wang | Aug 2000 | A |
6126672 | Berryman et al. | Oct 2000 | A |
6126673 | Kim et al. | Oct 2000 | A |
6129739 | Khosravi | Oct 2000 | A |
6136016 | Barbut et al. | Oct 2000 | A |
6146396 | Konya et al. | Nov 2000 | A |
6146404 | Kim et al. | Nov 2000 | A |
6152931 | Nadal et al. | Nov 2000 | A |
6152946 | Broome et al. | Nov 2000 | A |
6152947 | Ambrisco et al. | Nov 2000 | A |
6156061 | Wallace et al. | Dec 2000 | A |
6156062 | McGuinness | Dec 2000 | A |
6159230 | Samuels | Dec 2000 | A |
6165179 | Cathcart et al. | Dec 2000 | A |
6165198 | McGurk et al. | Dec 2000 | A |
6165199 | Barbut | Dec 2000 | A |
6165200 | Tsugita et al. | Dec 2000 | A |
6168579 | Tsugita et al. | Jan 2001 | B1 |
6168603 | Leslie et al. | Jan 2001 | B1 |
6168610 | Marin et al. | Jan 2001 | B1 |
6168622 | Mazzocchi | Jan 2001 | B1 |
6171327 | Daniel et al. | Jan 2001 | B1 |
6171328 | Addis | Jan 2001 | B1 |
6174318 | Bates et al. | Jan 2001 | B1 |
6179851 | Barbut et al. | Jan 2001 | B1 |
6179859 | Bates et al. | Jan 2001 | B1 |
6179860 | Fulton, III et al. | Jan 2001 | B1 |
6179861 | Khosravi et al. | Jan 2001 | B1 |
6187025 | Machek | Feb 2001 | B1 |
6193739 | Chevillon et al. | Feb 2001 | B1 |
6203561 | Ramee et al. | Mar 2001 | B1 |
6206931 | Cook et al. | Mar 2001 | B1 |
6214025 | Thistle et al. | Apr 2001 | B1 |
6214026 | Lepak et al. | Apr 2001 | B1 |
6221091 | Khosravi | Apr 2001 | B1 |
6224620 | Maahs | May 2001 | B1 |
6231588 | Zadno-Azizi | May 2001 | B1 |
6231589 | Wessman et al. | May 2001 | B1 |
6235044 | Root et al. | May 2001 | B1 |
6235045 | Barbut et al. | May 2001 | B1 |
6238412 | Dubrul et al. | May 2001 | B1 |
6241746 | Bosma et al. | Jun 2001 | B1 |
6245012 | Kleshinski | Jun 2001 | B1 |
6245087 | Addis | Jun 2001 | B1 |
6245088 | Lowery | Jun 2001 | B1 |
6245089 | Daniel et al. | Jun 2001 | B1 |
6251092 | Qin et al. | Jun 2001 | B1 |
6251122 | Tsukernik | Jun 2001 | B1 |
6254550 | McNamara et al. | Jul 2001 | B1 |
6254633 | Pinchuk et al. | Jul 2001 | B1 |
6258026 | Ravenscroft et al. | Jul 2001 | B1 |
6258115 | Dubrul | Jul 2001 | B1 |
6258120 | McKenzie et al. | Jul 2001 | B1 |
6261305 | Marotta et al. | Jul 2001 | B1 |
6264672 | Fisher | Jul 2001 | B1 |
6267776 | O'Connell | Jul 2001 | B1 |
6267777 | Bosma et al. | Jul 2001 | B1 |
6273900 | Nott et al. | Aug 2001 | B1 |
6273901 | Whitcher et al. | Aug 2001 | B1 |
6277125 | Barry et al. | Aug 2001 | B1 |
6277126 | Barry et al. | Aug 2001 | B1 |
6277138 | Levinson et al. | Aug 2001 | B1 |
6277139 | Levinson et al. | Aug 2001 | B1 |
6280451 | Bates et al. | Aug 2001 | B1 |
6287321 | Jang | Sep 2001 | B1 |
6290710 | Cryer et al. | Sep 2001 | B1 |
6299604 | Ragheb et al. | Oct 2001 | B1 |
6306163 | Fitz | Oct 2001 | B1 |
6309399 | Barbut et al. | Oct 2001 | B1 |
6312444 | Barbut | Nov 2001 | B1 |
6319268 | Ambrisco et al. | Nov 2001 | B1 |
6325815 | Kusleika et al. | Dec 2001 | B1 |
6325816 | Fulton, III et al. | Dec 2001 | B1 |
6328755 | Marshall | Dec 2001 | B1 |
6331183 | Suon | Dec 2001 | B1 |
6331184 | Abrams | Dec 2001 | B1 |
6334864 | Amplatz et al. | Jan 2002 | B1 |
6336934 | Gilson et al. | Jan 2002 | B1 |
6338739 | Datta et al. | Jan 2002 | B1 |
6340364 | Kanesaka | Jan 2002 | B2 |
6342062 | Suon et al. | Jan 2002 | B1 |
6342063 | DeVries et al. | Jan 2002 | B1 |
6344048 | Chin et al. | Feb 2002 | B1 |
6344049 | Levinson et al. | Feb 2002 | B1 |
6346116 | Brooks et al. | Feb 2002 | B1 |
6348041 | Klint | Feb 2002 | B1 |
6348063 | Yassour et al. | Feb 2002 | B1 |
6350271 | Kurz et al. | Feb 2002 | B1 |
6355051 | Sisskind et al. | Mar 2002 | B1 |
6358228 | Tubman et al. | Mar 2002 | B1 |
6361545 | Macoviak et al. | Mar 2002 | B1 |
6361546 | Khosravi | Mar 2002 | B1 |
6361547 | Hieshima | Mar 2002 | B1 |
6364895 | Greenhalgh | Apr 2002 | B1 |
6364896 | Addis | Apr 2002 | B1 |
6368338 | Konya et al. | Apr 2002 | B1 |
6371961 | Osborne et al. | Apr 2002 | B1 |
6371969 | Tsugita et al. | Apr 2002 | B1 |
6371970 | Khosravi et al. | Apr 2002 | B1 |
6371971 | Tsugita et al. | Apr 2002 | B1 |
6375670 | Greenhalgh | Apr 2002 | B1 |
6379374 | Hieshima et al. | Apr 2002 | B1 |
6380457 | Yurek et al. | Apr 2002 | B1 |
6383146 | Klint | May 2002 | B1 |
6383171 | Gifford et al. | May 2002 | B1 |
6383174 | Eder | May 2002 | B1 |
6383193 | Cathcart et al. | May 2002 | B1 |
6383196 | Leslie et al. | May 2002 | B1 |
6383205 | Samson et al. | May 2002 | B1 |
6383206 | Gillick et al. | May 2002 | B1 |
6391044 | Yadav et al. | May 2002 | B1 |
6391045 | Kim et al. | May 2002 | B1 |
6391052 | Buirge et al. | May 2002 | B2 |
6395014 | Macoviak et al. | May 2002 | B1 |
6402771 | Palmer et al. | Jun 2002 | B1 |
6402772 | Amplatz et al. | Jun 2002 | B1 |
6409742 | Fulton, III et al. | Jun 2002 | B1 |
6413235 | Parodi | Jul 2002 | B1 |
6416530 | DeVries et al. | Jul 2002 | B2 |
6419686 | McLeod et al. | Jul 2002 | B1 |
6423052 | Escano | Jul 2002 | B1 |
6423086 | Barbut et al. | Jul 2002 | B1 |
6425909 | Dieck et al. | Jul 2002 | B1 |
6428557 | Hilaire | Aug 2002 | B1 |
6428558 | Jones et al. | Aug 2002 | B1 |
6428559 | Johnson | Aug 2002 | B1 |
6432122 | Gilson et al. | Aug 2002 | B1 |
6436112 | Wensel et al. | Aug 2002 | B2 |
6436120 | Meglin | Aug 2002 | B1 |
6436121 | Blom | Aug 2002 | B1 |
6443926 | Kletschka | Sep 2002 | B1 |
6443971 | Boylan et al. | Sep 2002 | B1 |
6443972 | Bosma et al. | Sep 2002 | B1 |
6443979 | Stalker et al. | Sep 2002 | B1 |
6447530 | Ostrovsky et al. | Sep 2002 | B1 |
6447531 | Amplatz | Sep 2002 | B1 |
6454775 | Demarais et al. | Sep 2002 | B1 |
6458139 | Palmer et al. | Oct 2002 | B1 |
6458145 | Ravenscroft et al. | Oct 2002 | B1 |
6461370 | Gray et al. | Oct 2002 | B1 |
6468290 | Weldon et al. | Oct 2002 | B1 |
6468291 | Bates et al. | Oct 2002 | B2 |
6482222 | Bruckheimer et al. | Nov 2002 | B1 |
6485456 | Kletschka | Nov 2002 | B1 |
6485500 | Kokish et al. | Nov 2002 | B1 |
6485501 | Green | Nov 2002 | B1 |
6485502 | Don Michael et al. | Nov 2002 | B2 |
6491712 | O'Connor | Dec 2002 | B1 |
6494895 | Addis | Dec 2002 | B2 |
6497709 | Heath | Dec 2002 | B1 |
6499487 | McKenzie et al. | Dec 2002 | B1 |
6500166 | Zadno Azizi et al. | Dec 2002 | B1 |
6500191 | Addis | Dec 2002 | B2 |
6502606 | Klint | Jan 2003 | B2 |
6506203 | Boyle et al. | Jan 2003 | B1 |
6506205 | Goldberg et al. | Jan 2003 | B2 |
6508826 | Murphy et al. | Jan 2003 | B2 |
6511492 | Rosenbluth et al. | Jan 2003 | B1 |
6511496 | Huter et al. | Jan 2003 | B1 |
6511497 | Braun et al. | Jan 2003 | B1 |
6511503 | Burkett et al. | Jan 2003 | B1 |
6514273 | Voss et al. | Feb 2003 | B1 |
6517559 | O'Connell | Feb 2003 | B1 |
6520978 | Blackledge et al. | Feb 2003 | B1 |
6520983 | Colgan et al. | Feb 2003 | B1 |
6527746 | Oslund et al. | Mar 2003 | B1 |
6527791 | Fisher | Mar 2003 | B2 |
6527962 | Nadal | Mar 2003 | B1 |
6530935 | Wensel et al. | Mar 2003 | B2 |
6530939 | Hopkins et al. | Mar 2003 | B1 |
6530940 | Fisher | Mar 2003 | B2 |
6533770 | Lepulu et al. | Mar 2003 | B1 |
6533800 | Barbut | Mar 2003 | B1 |
6537293 | Berryman et al. | Mar 2003 | B1 |
6537294 | Boyle et al. | Mar 2003 | B1 |
6537296 | Levinson et al. | Mar 2003 | B2 |
6537297 | Tsugita et al. | Mar 2003 | B2 |
6540722 | Boyle et al. | Apr 2003 | B1 |
6540767 | Walak et al. | Apr 2003 | B1 |
6540768 | Diaz et al. | Apr 2003 | B1 |
6544221 | Kokish et al. | Apr 2003 | B1 |
6544276 | Azizi | Apr 2003 | B1 |
6544278 | Vrba et al. | Apr 2003 | B1 |
6544279 | Hopkins et al. | Apr 2003 | B1 |
6544280 | Daniel et al. | Apr 2003 | B1 |
6547759 | Fisher | Apr 2003 | B1 |
6551303 | Van Tassel et al. | Apr 2003 | B1 |
6551341 | Boylan et al. | Apr 2003 | B2 |
6551342 | Shen et al. | Apr 2003 | B1 |
6554849 | Jones et al. | Apr 2003 | B1 |
6558404 | Tsukernik | May 2003 | B2 |
6558405 | McInnes | May 2003 | B1 |
6558406 | Okada | May 2003 | B2 |
6562058 | Seguin et al. | May 2003 | B2 |
6565591 | Brady et al. | May 2003 | B2 |
6569147 | Evans et al. | May 2003 | B1 |
6569183 | Kim et al. | May 2003 | B1 |
6569184 | Huter | May 2003 | B2 |
6575995 | Huter et al. | Jun 2003 | B1 |
6575996 | Denison et al. | Jun 2003 | B1 |
6575997 | Palmer et al. | Jun 2003 | B1 |
6579303 | Amplatz | Jun 2003 | B2 |
6582396 | Parodi | Jun 2003 | B1 |
6582447 | Patel et al. | Jun 2003 | B1 |
6582448 | Boyle et al. | Jun 2003 | B1 |
6589227 | Klint | Jul 2003 | B2 |
6589230 | Gia et al. | Jul 2003 | B2 |
6589263 | Hopkins et al. | Jul 2003 | B1 |
6589264 | Barbut et al. | Jul 2003 | B1 |
6589265 | Palmer et al. | Jul 2003 | B1 |
6589266 | Whitcher et al. | Jul 2003 | B2 |
6592546 | Barbut et al. | Jul 2003 | B1 |
6592606 | Huter et al. | Jul 2003 | B2 |
6592616 | Stack et al. | Jul 2003 | B1 |
6596011 | Johnson et al. | Jul 2003 | B2 |
6599275 | Fischer, Jr. | Jul 2003 | B1 |
6599307 | Huter et al. | Jul 2003 | B1 |
6599308 | Amplatz | Jul 2003 | B2 |
6602271 | Adams et al. | Aug 2003 | B2 |
6602273 | Marshall | Aug 2003 | B2 |
6602280 | Chobotov | Aug 2003 | B2 |
6605102 | Mazzocchi et al. | Aug 2003 | B1 |
6607506 | Kletschka | Aug 2003 | B2 |
6610077 | Hancock et al. | Aug 2003 | B1 |
6611720 | Hata et al. | Aug 2003 | B2 |
6613074 | Mitelberg et al. | Sep 2003 | B1 |
6616679 | Khosravi et al. | Sep 2003 | B1 |
6616680 | Thielen | Sep 2003 | B1 |
6616681 | Hanson et al. | Sep 2003 | B2 |
6616682 | Joergensen et al. | Sep 2003 | B2 |
6620148 | Tsugita | Sep 2003 | B1 |
6620182 | Khosravi et al. | Sep 2003 | B1 |
6623450 | Dutta | Sep 2003 | B1 |
6623506 | McGuckin, Jr. et al. | Sep 2003 | B2 |
6629953 | Boyd | Oct 2003 | B1 |
6635068 | Dubrul et al. | Oct 2003 | B1 |
6635069 | Teoh et al. | Oct 2003 | B1 |
6635070 | Leeflang et al. | Oct 2003 | B2 |
6638293 | Makower et al. | Oct 2003 | B1 |
6638294 | Palmer | Oct 2003 | B1 |
6638372 | Abrams et al. | Oct 2003 | B1 |
6641590 | Palmer et al. | Nov 2003 | B1 |
6641605 | Stergiopulos | Nov 2003 | B1 |
6645160 | Heesch | Nov 2003 | B1 |
6645220 | Huter et al. | Nov 2003 | B1 |
6645221 | Richter | Nov 2003 | B1 |
6645222 | Parodi et al. | Nov 2003 | B1 |
6645223 | Boyle et al. | Nov 2003 | B2 |
6645224 | Gilson et al. | Nov 2003 | B2 |
6652554 | Wholey et al. | Nov 2003 | B1 |
6652557 | MacDonald | Nov 2003 | B1 |
6652558 | Patel et al. | Nov 2003 | B2 |
6656201 | Ferrera et al. | Dec 2003 | B2 |
6656202 | Papp et al. | Dec 2003 | B2 |
6656203 | Roth et al. | Dec 2003 | B2 |
6656204 | Ambrisco et al. | Dec 2003 | B2 |
6656351 | Boyle | Dec 2003 | B2 |
6660021 | Palmer et al. | Dec 2003 | B1 |
6663613 | Evans et al. | Dec 2003 | B1 |
6663650 | Sepetka et al. | Dec 2003 | B2 |
6663651 | Krolik et al. | Dec 2003 | B2 |
6663652 | Daniel et al. | Dec 2003 | B2 |
6676682 | Tsugita et al. | Jan 2004 | B1 |
6679902 | Boyle et al. | Jan 2004 | B1 |
6689144 | Gerberding | Feb 2004 | B2 |
6695813 | Boyle et al. | Feb 2004 | B1 |
6695865 | Boyle et al. | Feb 2004 | B2 |
6702834 | Boylan et al. | Mar 2004 | B1 |
6709450 | Kang et al. | Mar 2004 | B2 |
6712835 | Mazzocchi et al. | Mar 2004 | B2 |
6716207 | Farnholtz | Apr 2004 | B2 |
6716231 | Rafiee et al. | Apr 2004 | B1 |
6726701 | Gilson et al. | Apr 2004 | B2 |
6730064 | Ragheb et al. | May 2004 | B2 |
6755856 | Fierens et al. | Jun 2004 | B2 |
6758855 | Fulton, III et al. | Jul 2004 | B2 |
6761727 | Ladd | Jul 2004 | B1 |
6773446 | Dwyer et al. | Aug 2004 | B1 |
6773448 | Kusleika et al. | Aug 2004 | B2 |
6774278 | Ragheb et al. | Aug 2004 | B1 |
6780175 | Sachdeva et al. | Aug 2004 | B1 |
6793667 | Hebert et al. | Sep 2004 | B2 |
6793668 | Fisher | Sep 2004 | B1 |
6833002 | Stack et al. | Dec 2004 | B2 |
6855154 | Abdel-Gawwad | Feb 2005 | B2 |
6866677 | Douk et al. | Mar 2005 | B2 |
6866680 | Yassour et al. | Mar 2005 | B2 |
6872211 | White et al. | Mar 2005 | B2 |
6878153 | Linder et al. | Apr 2005 | B2 |
6896691 | Boylan et al. | May 2005 | B2 |
6929709 | Smith | Aug 2005 | B2 |
6932831 | Forber | Aug 2005 | B2 |
6939361 | Kleshinski | Sep 2005 | B1 |
6942682 | Vrba et al. | Sep 2005 | B2 |
6955685 | Escamilla et al. | Oct 2005 | B2 |
6964670 | Shah et al. | Nov 2005 | B1 |
6964674 | Matsuura et al. | Nov 2005 | B1 |
6969396 | Krolik et al. | Nov 2005 | B2 |
6974469 | Broome et al. | Dec 2005 | B2 |
6974473 | Barclay et al. | Dec 2005 | B2 |
6986784 | Weiser et al. | Jan 2006 | B1 |
6991641 | Diaz et al. | Jan 2006 | B2 |
7128073 | van der Burg et al. | Oct 2006 | B1 |
7166120 | Kusleika | Jan 2007 | B2 |
7174636 | Lowe | Feb 2007 | B2 |
7189249 | Hart et al. | Mar 2007 | B2 |
7255687 | Huang et al. | Aug 2007 | B2 |
7285130 | Austin | Oct 2007 | B2 |
7306619 | Palmer | Dec 2007 | B1 |
7371248 | Dapolito et al. | May 2008 | B2 |
7393358 | Malewicz | Jul 2008 | B2 |
7604649 | McGuckin et al. | Oct 2009 | B2 |
7666216 | Hogendijk et al. | Feb 2010 | B2 |
7708770 | Linder et al. | May 2010 | B2 |
7731722 | Lavelle et al. | Jun 2010 | B2 |
7766934 | Pal et al. | Aug 2010 | B2 |
20010000799 | Wessman et al. | May 2001 | A1 |
20010001817 | Humes | May 2001 | A1 |
20010005789 | Root et al. | Jun 2001 | A1 |
20010007947 | Kanesaka | Jul 2001 | A1 |
20010011181 | DiMatteo | Aug 2001 | A1 |
20010011182 | Dubrul et al. | Aug 2001 | A1 |
20010012951 | Bates et al. | Aug 2001 | A1 |
20010016755 | Addis | Aug 2001 | A1 |
20010020175 | Yassour et al. | Sep 2001 | A1 |
20010023358 | Tsukernik | Sep 2001 | A1 |
20010025187 | Okada | Sep 2001 | A1 |
20010031980 | Wensel et al. | Oct 2001 | A1 |
20010031981 | Evans et al. | Oct 2001 | A1 |
20010031982 | Peterson et al. | Oct 2001 | A1 |
20010039431 | DeVries et al. | Nov 2001 | A1 |
20010039432 | Whitcher et al. | Nov 2001 | A1 |
20010041908 | Levinson et al. | Nov 2001 | A1 |
20010041909 | Tsugita et al. | Nov 2001 | A1 |
20010041928 | Pavcnik et al. | Nov 2001 | A1 |
20010044632 | Daniel et al. | Nov 2001 | A1 |
20010044634 | Don Michael et al. | Nov 2001 | A1 |
20010053921 | Jang | Dec 2001 | A1 |
20020002383 | Sepetka et al. | Jan 2002 | A1 |
20020002384 | Gilson et al. | Jan 2002 | A1 |
20020004667 | Adams et al. | Jan 2002 | A1 |
20020016564 | Courtney et al. | Feb 2002 | A1 |
20020016609 | Wensel et al. | Feb 2002 | A1 |
20020022858 | Demond et al. | Feb 2002 | A1 |
20020022859 | Hogendijk | Feb 2002 | A1 |
20020026211 | Khosravi et al. | Feb 2002 | A1 |
20020026212 | Wholey et al. | Feb 2002 | A1 |
20020026213 | Gilson et al. | Feb 2002 | A1 |
20020032460 | Kusleika et al. | Mar 2002 | A1 |
20020032461 | Marshall | Mar 2002 | A1 |
20020042626 | Hanson et al. | Apr 2002 | A1 |
20020042627 | Brady et al. | Apr 2002 | A1 |
20020045915 | Balceta et al. | Apr 2002 | A1 |
20020045916 | Gray et al. | Apr 2002 | A1 |
20020045918 | Suon et al. | Apr 2002 | A1 |
20020049452 | Kurz et al. | Apr 2002 | A1 |
20020049468 | Streeter et al. | Apr 2002 | A1 |
20020052627 | Boylan et al. | May 2002 | A1 |
20020058904 | Boock et al. | May 2002 | A1 |
20020058911 | Gilson et al. | May 2002 | A1 |
20020058963 | Vale et al. | May 2002 | A1 |
20020058964 | Addis | May 2002 | A1 |
20020062133 | Gilson et al. | May 2002 | A1 |
20020062134 | Barbut et al. | May 2002 | A1 |
20020062135 | Mazzocchi et al. | May 2002 | A1 |
20020065507 | Zadno-Azizi | May 2002 | A1 |
20020068954 | Foster | Jun 2002 | A1 |
20020068955 | Khosravi | Jun 2002 | A1 |
20020072764 | Sepetka et al. | Jun 2002 | A1 |
20020072765 | Mazzocchi et al. | Jun 2002 | A1 |
20020077596 | McKenzie et al. | Jun 2002 | A1 |
20020082558 | Samson et al. | Jun 2002 | A1 |
20020082639 | Broome et al. | Jun 2002 | A1 |
20020087187 | Mazzocchi et al. | Jul 2002 | A1 |
20020090389 | Humes et al. | Jul 2002 | A1 |
20020091407 | Zadno-Azizi et al. | Jul 2002 | A1 |
20020091408 | Sutton et al. | Jul 2002 | A1 |
20020091409 | Sutton et al. | Jul 2002 | A1 |
20020095170 | Krolik et al. | Jul 2002 | A1 |
20020095171 | Belef | Jul 2002 | A1 |
20020095172 | Mazzocchi et al. | Jul 2002 | A1 |
20020095173 | Mazzocchi et al. | Jul 2002 | A1 |
20020095174 | Tsugita et al. | Jul 2002 | A1 |
20020099405 | Yurek et al. | Jul 2002 | A1 |
20020099407 | Becker et al. | Jul 2002 | A1 |
20020099435 | Stinson | Jul 2002 | A1 |
20020103501 | Diaz et al. | Aug 2002 | A1 |
20020107541 | Vale et al. | Aug 2002 | A1 |
20020111647 | Khairkhahan et al. | Aug 2002 | A1 |
20020111648 | Kusleika et al. | Aug 2002 | A1 |
20020111649 | Russo et al. | Aug 2002 | A1 |
20020116024 | Goldberg et al. | Aug 2002 | A1 |
20020120226 | Beck | Aug 2002 | A1 |
20020120286 | DoBrava et al. | Aug 2002 | A1 |
20020120287 | Huter | Aug 2002 | A1 |
20020123720 | Kusleika et al. | Sep 2002 | A1 |
20020123755 | Lowe et al. | Sep 2002 | A1 |
20020123759 | Amplatz | Sep 2002 | A1 |
20020123766 | Seguin et al. | Sep 2002 | A1 |
20020128679 | Turovskiy et al. | Sep 2002 | A1 |
20020128680 | Pavlovic | Sep 2002 | A1 |
20020128681 | Broome et al. | Sep 2002 | A1 |
20020133191 | Khosravi et al. | Sep 2002 | A1 |
20020133192 | Kusleika et al. | Sep 2002 | A1 |
20020138094 | Borillo et al. | Sep 2002 | A1 |
20020138095 | Mazzocchi et al. | Sep 2002 | A1 |
20020138096 | Hieshima | Sep 2002 | A1 |
20020138097 | Ostrovsky et al. | Sep 2002 | A1 |
20020143360 | Douk et al. | Oct 2002 | A1 |
20020143361 | Douk et al. | Oct 2002 | A1 |
20020143362 | Macoviak et al. | Oct 2002 | A1 |
20020151927 | Douk et al. | Oct 2002 | A1 |
20020151928 | Leslie et al. | Oct 2002 | A1 |
20020156520 | Boylan et al. | Oct 2002 | A1 |
20020161389 | Boyle et al. | Oct 2002 | A1 |
20020161390 | Mouw | Oct 2002 | A1 |
20020161391 | Murphy et al. | Oct 2002 | A1 |
20020161392 | Dubrul | Oct 2002 | A1 |
20020161393 | Demond et al. | Oct 2002 | A1 |
20020161394 | Macoviak et al. | Oct 2002 | A1 |
20020161395 | Douk et al. | Oct 2002 | A1 |
20020161396 | Jang et al. | Oct 2002 | A1 |
20020165557 | McAlister | Nov 2002 | A1 |
20020165573 | Barbut | Nov 2002 | A1 |
20020165576 | Boyle et al. | Nov 2002 | A1 |
20020165598 | Wahr et al. | Nov 2002 | A1 |
20020169472 | Douk et al. | Nov 2002 | A1 |
20020169474 | Kusleika et al. | Nov 2002 | A1 |
20020173815 | Hogendijk et al. | Nov 2002 | A1 |
20020173819 | Leeflang et al. | Nov 2002 | A1 |
20020177872 | Papp et al. | Nov 2002 | A1 |
20020177899 | Eum et al. | Nov 2002 | A1 |
20020183781 | Casey et al. | Dec 2002 | A1 |
20020183782 | Tsugita et al. | Dec 2002 | A1 |
20020183783 | Shadduck | Dec 2002 | A1 |
20020188313 | Johnson et al. | Dec 2002 | A1 |
20020188314 | Anderson et al. | Dec 2002 | A1 |
20020193824 | Boylan et al. | Dec 2002 | A1 |
20020193825 | McGuckin et al. | Dec 2002 | A1 |
20020193826 | McGuckin et al. | Dec 2002 | A1 |
20020193827 | McGuckin et al. | Dec 2002 | A1 |
20020193828 | Griffin et al. | Dec 2002 | A1 |
20020198561 | Amplatz | Dec 2002 | A1 |
20030004536 | Boylan et al. | Jan 2003 | A1 |
20030004537 | Boyle et al. | Jan 2003 | A1 |
20030004538 | Secrest et al. | Jan 2003 | A1 |
20030004539 | Linder et al. | Jan 2003 | A1 |
20030004540 | Linder et al. | Jan 2003 | A1 |
20030004541 | Linder et al. | Jan 2003 | A1 |
20030004542 | Wensel et al. | Jan 2003 | A1 |
20030009146 | Muni et al. | Jan 2003 | A1 |
20030009189 | Gilson et al. | Jan 2003 | A1 |
20030009190 | Kletschka et al. | Jan 2003 | A1 |
20030009191 | Wensel et al. | Jan 2003 | A1 |
20030014072 | Wensel et al. | Jan 2003 | A1 |
20030018354 | Roth et al. | Jan 2003 | A1 |
20030018355 | Goto et al. | Jan 2003 | A1 |
20030023263 | Krolik et al. | Jan 2003 | A1 |
20030023264 | Dieck et al. | Jan 2003 | A1 |
20030023265 | Forber | Jan 2003 | A1 |
20030032976 | Boucck | Feb 2003 | A1 |
20030032977 | Brady | Feb 2003 | A1 |
20030040772 | Hyodoh et al. | Feb 2003 | A1 |
20030045897 | Huter et al. | Mar 2003 | A1 |
20030045898 | Harrison et al. | Mar 2003 | A1 |
20030050662 | Michael | Mar 2003 | A1 |
20030055452 | Joergensen et al. | Mar 2003 | A1 |
20030055480 | Fischell et al. | Mar 2003 | A1 |
20030060843 | Boucher | Mar 2003 | A1 |
20030060844 | Borillo et al. | Mar 2003 | A1 |
20030065354 | Boyle et al. | Apr 2003 | A1 |
20030065355 | Weber | Apr 2003 | A1 |
20030065356 | Tsugita et al. | Apr 2003 | A1 |
20030069596 | Eskuri | Apr 2003 | A1 |
20030073979 | Naimark et al. | Apr 2003 | A1 |
20030074019 | Gray et al. | Apr 2003 | A1 |
20030074054 | Duerig et al. | Apr 2003 | A1 |
20030078614 | Salahieh et al. | Apr 2003 | A1 |
20030083608 | Evans et al. | May 2003 | A1 |
20030083692 | Vrba et al. | May 2003 | A1 |
20030083693 | Daniel et al. | May 2003 | A1 |
20030088211 | Anderson et al. | May 2003 | A1 |
20030088266 | Bowlin | May 2003 | A1 |
20030093110 | Vale | May 2003 | A1 |
20030093112 | Addis | May 2003 | A1 |
20030097094 | Ouriel et al. | May 2003 | A1 |
20030097145 | Goldberg et al. | May 2003 | A1 |
20030100917 | Boyle et al. | May 2003 | A1 |
20030100918 | Duane | May 2003 | A1 |
20030100919 | Hopkins et al. | May 2003 | A1 |
20030105472 | McAlister | Jun 2003 | A1 |
20030105484 | Boyle et al. | Jun 2003 | A1 |
20030105486 | Murphy et al. | Jun 2003 | A1 |
20030109824 | Anderson et al. | Jun 2003 | A1 |
20030109897 | Walak et al. | Jun 2003 | A1 |
20030109916 | Michael | Jun 2003 | A1 |
20030114879 | Euteneuer et al. | Jun 2003 | A1 |
20030114880 | Hansen et al. | Jun 2003 | A1 |
20030120303 | Boyle et al. | Jun 2003 | A1 |
20030120304 | Kaganov et al. | Jun 2003 | A1 |
20030125764 | Brady et al. | Jul 2003 | A1 |
20030125765 | Blackledge et al. | Jul 2003 | A1 |
20030130680 | Russell | Jul 2003 | A1 |
20030130681 | Ungs | Jul 2003 | A1 |
20030130682 | Broome et al. | Jul 2003 | A1 |
20030130684 | Brady et al. | Jul 2003 | A1 |
20030130685 | Daniel et al. | Jul 2003 | A1 |
20030130686 | Daniel et al. | Jul 2003 | A1 |
20030130687 | Daniel et al. | Jul 2003 | A1 |
20030130688 | Daniel et al. | Jul 2003 | A1 |
20030135232 | Douk et al. | Jul 2003 | A1 |
20030135233 | Bates et al. | Jul 2003 | A1 |
20030139764 | Levinson et al. | Jul 2003 | A1 |
20030139765 | Patel et al. | Jul 2003 | A1 |
20030144685 | Boyle et al. | Jul 2003 | A1 |
20030144686 | Martinez et al. | Jul 2003 | A1 |
20030144687 | Brady et al. | Jul 2003 | A1 |
20030144688 | Brady et al. | Jul 2003 | A1 |
20030144689 | Brady et al. | Jul 2003 | A1 |
20030150821 | Bates et al. | Aug 2003 | A1 |
20030153935 | Mialhe | Aug 2003 | A1 |
20030153942 | Wang et al. | Aug 2003 | A1 |
20030153943 | Michael et al. | Aug 2003 | A1 |
20030153944 | Phung et al. | Aug 2003 | A1 |
20030153945 | Patel et al. | Aug 2003 | A1 |
20030158518 | Schonholz et al. | Aug 2003 | A1 |
20030158574 | Esch et al. | Aug 2003 | A1 |
20030158575 | Boylan et al. | Aug 2003 | A1 |
20030163158 | White | Aug 2003 | A1 |
20030163159 | Patel et al. | Aug 2003 | A1 |
20030167068 | Amplatz | Sep 2003 | A1 |
20030167069 | Gonzales et al. | Sep 2003 | A1 |
20030171769 | Barbut | Sep 2003 | A1 |
20030171770 | Kusleika et al. | Sep 2003 | A1 |
20030171771 | Anderson et al. | Sep 2003 | A1 |
20030171772 | Amplatz | Sep 2003 | A1 |
20030171800 | Bicek et al. | Sep 2003 | A1 |
20030171803 | Shimon | Sep 2003 | A1 |
20030176884 | Berrada et al. | Sep 2003 | A1 |
20030176885 | Broome et al. | Sep 2003 | A1 |
20030176886 | Wholey et al. | Sep 2003 | A1 |
20030176887 | Petersen | Sep 2003 | A1 |
20030176888 | O'Connell | Sep 2003 | A1 |
20030176889 | Boyle et al. | Sep 2003 | A1 |
20030181942 | Sutton et al. | Sep 2003 | A1 |
20030181943 | Daniel et al. | Sep 2003 | A1 |
20030717769 | Barbut | Sep 2003 | |
20030187474 | Keegan et al. | Oct 2003 | A1 |
20030187475 | Tsugita et al. | Oct 2003 | A1 |
20030187495 | Cully et al. | Oct 2003 | A1 |
20030191492 | Gellman et al. | Oct 2003 | A1 |
20030191493 | Epstein et al. | Oct 2003 | A1 |
20030195554 | Shen et al. | Oct 2003 | A1 |
20030195555 | Khairkhahan et al. | Oct 2003 | A1 |
20030195556 | Stack et al. | Oct 2003 | A1 |
20030199819 | Beck | Oct 2003 | A1 |
20030199917 | Knudson et al. | Oct 2003 | A1 |
20030199918 | Patel et al. | Oct 2003 | A1 |
20030199919 | Palmer et al. | Oct 2003 | A1 |
20030199920 | Boylan et al. | Oct 2003 | A1 |
20030199921 | Palmer et al. | Oct 2003 | A1 |
20030204168 | Bosma et al. | Oct 2003 | A1 |
20030204202 | Palmer et al. | Oct 2003 | A1 |
20030204203 | Khairkhahan et al. | Oct 2003 | A1 |
20030208222 | Zadno-Azizi | Nov 2003 | A1 |
20030208224 | Broome | Nov 2003 | A1 |
20030208225 | Goll et al. | Nov 2003 | A1 |
20030208226 | Bruckheimer et al. | Nov 2003 | A1 |
20030208227 | Thomas | Nov 2003 | A1 |
20030208228 | Gilson et al. | Nov 2003 | A1 |
20030208229 | Kletschka | Nov 2003 | A1 |
20030208253 | Beyer et al. | Nov 2003 | A1 |
20030212428 | Richter | Nov 2003 | A1 |
20030212429 | Keegan et al. | Nov 2003 | A1 |
20030212431 | Brady et al. | Nov 2003 | A1 |
20030212432 | Khairkhahan et al. | Nov 2003 | A1 |
20030212433 | Ambrisco et al. | Nov 2003 | A1 |
20030212434 | Thielen | Nov 2003 | A1 |
20030216774 | Larson | Nov 2003 | A1 |
20030220665 | Eskuri et al. | Nov 2003 | A1 |
20030220667 | van der Burg et al. | Nov 2003 | A1 |
20030225418 | Esksuri et al. | Dec 2003 | A1 |
20030225435 | Hunter et al. | Dec 2003 | A1 |
20030229374 | Brady et al. | Dec 2003 | A1 |
20030233117 | Adams et al. | Dec 2003 | A1 |
20040006364 | Ladd | Jan 2004 | A1 |
20040006365 | Brady et al. | Jan 2004 | A1 |
20040006370 | Tsugita | Jan 2004 | A1 |
20040015152 | Day | Jan 2004 | A1 |
20040039412 | Isshiki et al. | Feb 2004 | A1 |
20040049226 | Keegan et al. | Mar 2004 | A1 |
20040054394 | Lee | Mar 2004 | A1 |
20040054395 | Lee et al. | Mar 2004 | A1 |
20040059372 | Tsugita | Mar 2004 | A1 |
20040064067 | Ward | Apr 2004 | A1 |
20040064179 | Linder et al. | Apr 2004 | A1 |
20040068271 | McAlister | Apr 2004 | A1 |
20040078044 | Kear et al. | Apr 2004 | A1 |
20040082962 | Demarais et al. | Apr 2004 | A1 |
20040088038 | Dehnad et al. | May 2004 | A1 |
20040093009 | Denison et al. | May 2004 | A1 |
20040093012 | Cully et al. | May 2004 | A1 |
20040093016 | Root et al. | May 2004 | A1 |
20040093059 | Lee et al. | May 2004 | A1 |
20040098022 | Barone | May 2004 | A1 |
20040098026 | Joergensen et al. | May 2004 | A1 |
20040098033 | Leeflang et al. | May 2004 | A1 |
20040098112 | DiMatteo et al. | May 2004 | A1 |
20040102719 | Keith et al. | May 2004 | A1 |
20040106944 | Daniel et al. | Jun 2004 | A1 |
20040116831 | Vrba | Jun 2004 | A1 |
20040133232 | Rosenbluth et al. | Jul 2004 | A1 |
20040138696 | Drasler et al. | Jul 2004 | A1 |
20040153118 | Clubb et al. | Aug 2004 | A1 |
20040158278 | Becker et al. | Aug 2004 | A1 |
20040162576 | Barbut et al. | Aug 2004 | A1 |
20040164030 | Lowe et al. | Aug 2004 | A1 |
20040167567 | Cano et al. | Aug 2004 | A1 |
20040176794 | Khosravi | Sep 2004 | A1 |
20040176833 | Pavcnik et al. | Sep 2004 | A1 |
20040199203 | Oslund et al. | Oct 2004 | A1 |
20040204737 | Boismier et al. | Oct 2004 | A1 |
20040215322 | Kerr | Oct 2004 | A1 |
20040225321 | Krolik et al. | Nov 2004 | A1 |
20040236369 | Dubrul | Nov 2004 | A1 |
20050004663 | Llanos et al. | Jan 2005 | A1 |
20050021125 | Stack et al. | Jan 2005 | A1 |
20050027345 | Horan et al. | Feb 2005 | A1 |
20050038468 | Panetta et al. | Feb 2005 | A1 |
20050038503 | Greenhaigh | Feb 2005 | A1 |
20050043743 | Dennis | Feb 2005 | A1 |
20050043756 | Lavelle et al. | Feb 2005 | A1 |
20050043780 | Gifford et al. | Feb 2005 | A1 |
20050049668 | Jones et al. | Mar 2005 | A1 |
20050126979 | Lowe et al. | Jun 2005 | A1 |
20050137696 | Salahieh et al. | Jun 2005 | A1 |
20050149110 | Wholey et al. | Jul 2005 | A1 |
20050165480 | Jordan et al. | Jul 2005 | A1 |
20050177186 | Cully et al. | Aug 2005 | A1 |
20050177246 | Datta et al. | Aug 2005 | A1 |
20050197688 | Theron et al. | Sep 2005 | A1 |
20050209634 | Brady et al. | Sep 2005 | A1 |
20050216053 | Douk et al. | Sep 2005 | A1 |
20050217767 | Barvosa-Carter et al. | Oct 2005 | A1 |
20050228474 | Laguna | Oct 2005 | A1 |
20060009798 | Callister et al. | Jan 2006 | A1 |
20060009799 | Kleshinski et al. | Jan 2006 | A1 |
20060020334 | Lashinski et al. | Jan 2006 | A1 |
20060030923 | Gunderson | Feb 2006 | A1 |
20060074474 | Theron | Apr 2006 | A1 |
20060100544 | Ayala et al. | May 2006 | A1 |
20060100545 | Ayala et al. | May 2006 | A1 |
20060161241 | Barbut et al. | Jul 2006 | A1 |
20060184194 | Pal et al. | Aug 2006 | A1 |
20060200221 | Malewicz | Sep 2006 | A1 |
20060229660 | Pal et al. | Oct 2006 | A1 |
20060264707 | Kinney | Nov 2006 | A1 |
20060287668 | Fawzi et al. | Dec 2006 | A1 |
20070038241 | Pal | Feb 2007 | A1 |
20070100372 | Schaeffer | May 2007 | A1 |
20070112374 | Paul, Jr. et al. | May 2007 | A1 |
20070129752 | Webler et al. | Jun 2007 | A1 |
20070149996 | Coughlin | Jun 2007 | A1 |
20070167974 | Cully et al. | Jul 2007 | A1 |
20070185521 | Bui et al. | Aug 2007 | A1 |
20070250108 | Boyle et al. | Oct 2007 | A1 |
20070288054 | Tanaka et al. | Dec 2007 | A1 |
20080015518 | Huang et al. | Jan 2008 | A1 |
20080027481 | Gilson et al. | Jan 2008 | A1 |
20080103522 | Steingisser et al. | May 2008 | A1 |
20080154236 | Elkins et al. | Jun 2008 | A1 |
20080167629 | Dann et al. | Jul 2008 | A1 |
20080255587 | Cully et al. | Oct 2008 | A1 |
20080255606 | Mitra et al. | Oct 2008 | A1 |
20080262337 | Falwell et al. | Oct 2008 | A1 |
20080275569 | Lesh | Nov 2008 | A1 |
Number | Date | Country |
---|---|---|
34 29 850 | Feb 1986 | DE |
1127556 | Aug 2001 | EP |
1310219 | May 2003 | EP |
1516601 | Mar 2005 | EP |
1557137 | Jul 2005 | EP |
WO 9203097 | Mar 1992 | WO |
WO 9610591 | Apr 1996 | WO |
WO 9916382 | Apr 1999 | WO |
WO 9923976 | May 1999 | WO |
WO 9944510 | Sep 1999 | WO |
WO 0182831 | Nov 2001 | WO |
WO 03077799 | Sep 2003 | WO |
WO 2006138391 | Dec 2006 | WO |
Entry |
---|
Rubicon Embolic Filter, The Next Generation of EM, Rubicon Medical, www.rubiconmed.com. |
Heeschen et al., Nature Medicine 7 (2001), No. 7, pp. 833-839. |
Johnson et al., Circulation Research 94 (2004), No. 2, pp. 262-268. |
International Search Report and Written Opinion for PCT/US2007/020300. |
Brochure, “Shuttle Select™ System for Carotid Artery Access,” (2004), pp. 1-3. |
Brochure, “Slip-Cath® Angiographic Selective Catheters,” (2004), pp. 1-6. |
Finol, E.A. et al., “Performance Assessment of Embolic Protection Filters for Carotid Artery Stenting,” Modelling in Medicine and Biology IV, (2005), vol. 8, pp. 133. |
Grummon, David S. et al., Appl. Phys. Lett., 82, 2727 (2003), pp. 2727. |
Number | Date | Country | |
---|---|---|---|
20070088383 A1 | Apr 2007 | US |
Number | Date | Country | |
---|---|---|---|
60723255 | Oct 2005 | US |